Correspondence| Volume 65, 104037, September 2022

Download started.


Satralizumab might not be enough. Olamkicept (sgp130Fc) in Neuromyelitis Optica Spectrum Disorder


      • Satralizumab, an antibody against IL-6R, has been recently approved in Neuromyelitis Optica Spectrum Disorder(NMOSD).
      • Targeting IL-6 and IL-6 receptor (as it happens with Satralizumab) results in inhibition of both pro and anti-inflammatory pathways of IL-6. The detrimental role of IL-6 in NMOSD could be played by the trans-signaling pathway (the pro-inflammatory one).
      • sgp130Fc(Olamkicept) is a monoclonal antibody that prevents only the pro-inflammatory pathway of IL-6 to be activated, it could be a better way to target IL-6 pathway in Neuromyelitis Optica Spectrum Disorder.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Yamamura T.
        • Kleiter I.
        • Fujihara K.
        • et al.
        Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
        New Engl. J. Med. 2019; 381: 2114-2124
        • Fujihara K.
        • Bennett J.L.
        • de Seze J.
        • et al.
        Interleukin-6 in Neuromyelitis Optica Spectrum Disorder pathophysiology.
        Neurol. Neuroimmunol. Neuroinflamm. 2020; 7: e841
        • Rose-John S
        IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.
        Int. J. Biol. Sci. 2012; 8: 1237-1247
        • Rose-John S
        Blocking only the bad side of IL-6 in inflammation and cancer.
        Cytokine. 2021; 148155690
        • Schreiber S.
        • Aden K.
        • Bernardes J.P.
        • et al.
        Therapeutic interleukin-6 trans-signaling inhibition by Olamkicept (sgp130Fc) in patients with active inflammatory bowel disease.
        Gastroenterology. 2021; 160 (e2311): 2354-2366
        • Campbell I.L.
        • Erta M.
        • Lim S.L.
        • Frausto R.
        • May U.
        • Rose-John S.
        • Scheller J.
        • Hidalgo J.
        Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain.
        J. Neurosci. 2014; 34 (Feb 12): 2503-2513
        • Rothaug M.
        • Becker-Pauly C.
        • Rose-John S
        The role of interleukin-6 signaling in nervous tissue.
        Biochim. Biophys. Acta. 2016; 1863 (Jun): 1218-1227
        • Chen T.
        • Bosco D.B.
        • Ying Y.
        • Tian D.S.
        • Wu L.J.
        The emerging role of microglia in Neuromyelitis Optica.
        Front. Immunol. 2021; 12 (Feb 19)616301
        • Takeshita Y.
        • Fujikawa S.
        • Serizawa K.
        • Fujisawa M.
        • Matsuo K.
        • Nemoto J.
        • Shimizu F.
        • Sano Y.
        • Tomizawa-Shinohara H.
        • Miyake S.
        • Ransohoff R.M.
        • Kanda T.
        New BBB model reveals that IL-6 blockade suppressed the BBB disorder, preventing onset of NMOSD.
        Neurol. Neuroimmunol. Neuroinflamm. 2021; 8 (Oct 19): e1076
        • Wang H.
        • Wang K.
        • Zhong X.
        • Dai Y.
        • Qiu W.
        • Wu A.
        • Hu X.
        Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in Neuromyelitis Optica.
        Neuroimmunomodulation. 2012; 19: 304-308